Last reviewed · How we verify
Enoksetin — Competitive Intelligence Brief
marketed
enoxacin
RISC-loading complex subunit TARBP2
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Enoksetin (ENOXACIN).
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Enoksetin TARGET | ENOXACIN | marketed | enoxacin | RISC-loading complex subunit TARBP2 | 1991-01-01 | |
| ENOXA® | ENOXA® | Les Laboratoires des Médicaments Stériles | marketed | RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase | ||
| Geninax | GARENOXACIN | marketed | garenoxacin | 2007-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (enoxacin class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Enoksetin CI watch — RSS
- Enoksetin CI watch — Atom
- Enoksetin CI watch — JSON
- Enoksetin alone — RSS
- Whole enoxacin class — RSS
Cite this brief
Drug Landscape (2026). Enoksetin — Competitive Intelligence Brief. https://druglandscape.com/ci/enoxacin. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab